Latest research on Riluzole

A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Latest findings

As a consequence, besides Riluzole, 2-amino-6-trifluoromethoxybenzothiazole [2], only palliative treatments are applied to improve the quality of life of ALS patients. [source, 2016]
Riluzole increases the life span of the patients by an average of 2–3 months [3], an effect that was reproduced in different clinical trials [4]. [source, 2016]
These orphan drugs are Imiglucerase, sapropterin dihydrochloride, recombinant coagulation Factor VIII, coagulation factor VIIa, human coagulation Factor VIII, human prothrombin complex concentrate, bosentan, Iloprost, ambrisentan, recombinant human Growth hormone, Busulfan, teniposide, Mitoxantrone, Imatinib, Dasatinib, nilotinib, meisoindigo, Arsenious Acid, homoharringtonine, rituximab, sorafenib, Danazol, Riluzole and poractant alfa. [source, 2016]
There are five orphan drugs defined as DDD by WHO, including Imiglucerase 300U, bosentan 250 mg, iloprost 50 ug, Danazol 600 mg, Riluzole 100 mg [20]. [source, 2016]
The protective effect of Riluzole has been examined in various models where excitotoxicity has an important role in MN death including organotypic-based models [5] and animal models of spinal cord injury [6]. [source, 2016]
); addition of Riluzole (5 μM) was also assayed as positive control. [source, 2016]
In contrast, slices treated with THA plus CD1, CD2 or Riluzole (5 μM), used as a positive control, presented a significant neuroprotective effect on MNs preservation (20±2, 19±3 and 29±4, respectively) (Fig 2A–2B). [source, 2016]
Related to the former, as mentioned, Riluzole, the only compound that presents limited benefits in ALS patients, exerts it effect mainly by reducing excitotoxicity. [source, 2016]
Even though we still lack a definitive cure for ALS, the Food and Drug Administration (FDA) has already approved the first molecule to treat the disease, that is, Riluzole. [source, 2016]
Treatment with Riluzole of ALS patients in clinical trials only elicited a three-month improvement of survival rate, with the subjects needing constant monitoring of liver damage and other side effects [64]. [source, 2016]